Genelux Corporation executives will discuss company developments at the Piper Sandler Healthcare Conference on December 3, 2025.
Quiver AI Summary
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, CEO, and Chairman, Thomas Zindrick, along with Chief Financial Officer, Matt Pulisic, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at noon ET in New York City. The event will be available through a live webcast, with an archived replay accessible on the company’s website afterward. Genelux is focused on developing oncolytic immunotherapies, specifically its candidate Olvi-Vec, which is currently being evaluated in multiple clinical trials for various types of cancer including ovarian and lung cancer. The company's research is based on its proprietary CHOICE™ platform, which supports the development of oncolytic virus therapies. Further information can be found on their website and social media channels.
Potential Positives
- Participation of CEO and CFO in a prestigious healthcare conference highlights the company's leadership visibility and engagement with investors.
- Presentation of the clinical trials involving Olvi-Vec demonstrates significant progress in the development of advanced therapies for difficult-to-treat cancers, reinforcing the company's innovation potential.
- The archived webcast of the fireside chat provides ongoing access to information for investors, enhancing transparency and communication from the company.
Potential Negatives
- None
FAQ
What is the purpose of the fireside chat on December 3, 2025?
The fireside chat aims to discuss Genelux Corporation's progress and developments in immuno-oncology with key executives.
How can I access the live webcast of the fireside chat?
The live webcast can be accessed via a link provided in the press release or on Genelux's investor website.
What is Olvi-Vec and its current clinical trials?
Olvi-Vec is an oncolytic immunotherapy currently in multiple U.S.-based clinical trials for treating ovarian and lung cancers.
What is Genelux Corporation's focus in biopharmaceuticals?
Genelux focuses on developing next-generation oncolytic immunotherapies for challenging solid tumor types in late-stage clinical trials.
Where can I find more information about Genelux Corporation?
More information can be found on their official website at www.genelux.com or by following them on social media.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GNLX Hedge Fund Activity
We have seen 27 institutional investors add shares of $GNLX stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FLPUTNAM INVESTMENT MANAGEMENT CO added 263,131 shares (+708.1%) to their portfolio in Q3 2025, for an estimated $1,105,150
- HEIGHTS CAPITAL MANAGEMENT, INC removed 238,366 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $684,110
- MAI CAPITAL MANAGEMENT removed 204,560 shares (-86.5%) from their portfolio in Q3 2025, for an estimated $859,152
- DAUNTLESS INVESTMENT GROUP, LLC removed 123,194 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $517,414
- OSAIC HOLDINGS, INC. added 107,950 shares (+2390.4%) to their portfolio in Q3 2025, for an estimated $453,390
- BANK OF AMERICA CORP /DE/ removed 85,198 shares (-20.8%) from their portfolio in Q3 2025, for an estimated $357,831
- OMERS ADMINISTRATION CORP removed 79,700 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $228,739
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GNLX Analyst Ratings
Wall Street analysts have issued reports on $GNLX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 10/21/2025
- LUCID CAPITAL MARKETS issued a "Buy" rating on 07/21/2025
To track analyst ratings and price targets for $GNLX, check out Quiver Quantitative's $GNLX forecast page.
$GNLX Price Targets
Multiple analysts have issued price targets for $GNLX recently. We have seen 2 analysts offer price targets for $GNLX in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Chad Messer from Lake Street set a target price of $16.0 on 10/21/2025
- Christopher Liu from LUCID CAPITAL MARKETS set a target price of $10.0 on 07/21/2025
Full Release
WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37 th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY.
A live webcast of the fireside chat can be found here . Following the live webcast, an archived replay will be available on the Company’s website https://investors.genelux.com/ .
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn .
Investor Contact
Austin Murtagh
Precision AQ
[email protected]
Media Contact
Ashley Murphy
Precision AQ
[email protected]
Source: Genelux Corporation
